Sanofi raises annual outlook as Dupixent drives double-digit sales growth
Sanofi ($SAN-EURONEXT) increased its 2026 outlook to low-teens sales growth and mid-teens growth in business earnings per share, both at constant exchange rates. Third-quarter 2026 sales reached €14.44 billion, increasing 14.3% on that basis. Dupixent revenue climbed 34.8% to €5.7 billion, while recently launched medicines generated €1.4 billion, up 31.4%. Business EPS reached €3.55, rising 19.6% at constant rates. Growth was uneven across the portfolio: vaccine sales fell 6.6% to €3.2 billion,
0